DIACEREIN AS THE DRUG OF CHOICE IN THE THERAPY OF KNEE OSTEOARTHRITIS WITH SECONDARY RECURRENT SYNOVITIS
Objective: to evaluate the efficacy and tolerability of diacerein in the therapy of primary knee osteoarthritis (OA) with secondary recurrent synovitis.Subjects and methods. The 3-month open-label randomized controlled trial enrolled 133 patients with OA. Group 1 consisted of 68 subjects (42 women a...
Saved in:
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
IMA PRESS LLC
2016-02-01
|
| Series: | Научно-практическая ревматология |
| Subjects: | |
| Online Access: | https://rsp.mediar-press.net/rsp/article/view/2152 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1839568386926837760 |
|---|---|
| author | M. I. Udovika |
| author_facet | M. I. Udovika |
| author_sort | M. I. Udovika |
| collection | DOAJ |
| description | Objective: to evaluate the efficacy and tolerability of diacerein in the therapy of primary knee osteoarthritis (OA) with secondary recurrent synovitis.Subjects and methods. The 3-month open-label randomized controlled trial enrolled 133 patients with OA. Group 1 consisted of 68 subjects (42 women and 26 men; mean age 54.22±4.29 years) who took diacerein 100 mg/day for 3 months. Group 2 (a control group) included 65 subjects (45 women and 20 men; mean age 53.50±3.27 years) who received chondroitin sulfate 1000 mg/day + glucosamine sulfate 1000 mg/day and meloxicam 7.5 mg/day for 3 months too.Results and discussion. After a therapy cycle, Group 1 patients displayed a statistically significant decrease in the Lequesne index from 13.92±2.16 to 5.95±0.92 (p=0.00005); in Group 2, this index significantly reduced from 16.72±1.78 to 10.76±1.54 (p=0.001). Pain intensity on the visual analogue scale decreased significantly from 70.88±7.06 to 22.05±6.36 mm (p<0.00001) in Group 1 and from 72.46±7.02 to 39.84±6.67 mm (p<0.0004) in Group 2. A persistent analgesic effect was achieved at weeks 6 and 7 in Groups 1 and 2, respectively. The therapeutic effect was estimated as very good and good by 48 and 52% of the patients, respectively, in Group 1 and as good and moderate by 43 and 57% in Group 2. Three months after a therapy cycle effusion in the affected knee substantially increased (from 21.70±6.29 to 29.16±3.63 ml; p<0.001) in Group 2 and slightly increased (from 5.86±3.10 to 6.12±1.09 ml; p>0.05) in Group 1, which confirms the steady-state effect of diacerein. The results of the performed open-label randomized clinical trial showed marked analgesic and anti-inflammatory effect of diacerein and allow to recommend it as the drug of choice to treat knee OA with secondary recurrent synovitis. |
| format | Article |
| id | doaj-art-43f53f51234a47519c3e314f47b10a06 |
| institution | Matheson Library |
| issn | 1995-4484 1995-4492 |
| language | Russian |
| publishDate | 2016-02-01 |
| publisher | IMA PRESS LLC |
| record_format | Article |
| series | Научно-практическая ревматология |
| spelling | doaj-art-43f53f51234a47519c3e314f47b10a062025-08-04T17:03:56ZrusIMA PRESS LLCНаучно-практическая ревматология1995-44841995-44922016-02-0153661461810.14412/1995-4484-2015-614-6182032DIACEREIN AS THE DRUG OF CHOICE IN THE THERAPY OF KNEE OSTEOARTHRITIS WITH SECONDARY RECURRENT SYNOVITISM. I. Udovika0Medical Sanitary Unit, Ministry of Internal Affairs of Russia in the Ulyanovsk Region, Ulyanovsk, Russia 17, Orlov St., Ulyanovsk 432071Objective: to evaluate the efficacy and tolerability of diacerein in the therapy of primary knee osteoarthritis (OA) with secondary recurrent synovitis.Subjects and methods. The 3-month open-label randomized controlled trial enrolled 133 patients with OA. Group 1 consisted of 68 subjects (42 women and 26 men; mean age 54.22±4.29 years) who took diacerein 100 mg/day for 3 months. Group 2 (a control group) included 65 subjects (45 women and 20 men; mean age 53.50±3.27 years) who received chondroitin sulfate 1000 mg/day + glucosamine sulfate 1000 mg/day and meloxicam 7.5 mg/day for 3 months too.Results and discussion. After a therapy cycle, Group 1 patients displayed a statistically significant decrease in the Lequesne index from 13.92±2.16 to 5.95±0.92 (p=0.00005); in Group 2, this index significantly reduced from 16.72±1.78 to 10.76±1.54 (p=0.001). Pain intensity on the visual analogue scale decreased significantly from 70.88±7.06 to 22.05±6.36 mm (p<0.00001) in Group 1 and from 72.46±7.02 to 39.84±6.67 mm (p<0.0004) in Group 2. A persistent analgesic effect was achieved at weeks 6 and 7 in Groups 1 and 2, respectively. The therapeutic effect was estimated as very good and good by 48 and 52% of the patients, respectively, in Group 1 and as good and moderate by 43 and 57% in Group 2. Three months after a therapy cycle effusion in the affected knee substantially increased (from 21.70±6.29 to 29.16±3.63 ml; p<0.001) in Group 2 and slightly increased (from 5.86±3.10 to 6.12±1.09 ml; p>0.05) in Group 1, which confirms the steady-state effect of diacerein. The results of the performed open-label randomized clinical trial showed marked analgesic and anti-inflammatory effect of diacerein and allow to recommend it as the drug of choice to treat knee OA with secondary recurrent synovitis.https://rsp.mediar-press.net/rsp/article/view/2152osteoarthritisdiacereinlequesne indexinflammationpainsynovitis |
| spellingShingle | M. I. Udovika DIACEREIN AS THE DRUG OF CHOICE IN THE THERAPY OF KNEE OSTEOARTHRITIS WITH SECONDARY RECURRENT SYNOVITIS Научно-практическая ревматология osteoarthritis diacerein lequesne index inflammation pain synovitis |
| title | DIACEREIN AS THE DRUG OF CHOICE IN THE THERAPY OF KNEE OSTEOARTHRITIS WITH SECONDARY RECURRENT SYNOVITIS |
| title_full | DIACEREIN AS THE DRUG OF CHOICE IN THE THERAPY OF KNEE OSTEOARTHRITIS WITH SECONDARY RECURRENT SYNOVITIS |
| title_fullStr | DIACEREIN AS THE DRUG OF CHOICE IN THE THERAPY OF KNEE OSTEOARTHRITIS WITH SECONDARY RECURRENT SYNOVITIS |
| title_full_unstemmed | DIACEREIN AS THE DRUG OF CHOICE IN THE THERAPY OF KNEE OSTEOARTHRITIS WITH SECONDARY RECURRENT SYNOVITIS |
| title_short | DIACEREIN AS THE DRUG OF CHOICE IN THE THERAPY OF KNEE OSTEOARTHRITIS WITH SECONDARY RECURRENT SYNOVITIS |
| title_sort | diacerein as the drug of choice in the therapy of knee osteoarthritis with secondary recurrent synovitis |
| topic | osteoarthritis diacerein lequesne index inflammation pain synovitis |
| url | https://rsp.mediar-press.net/rsp/article/view/2152 |
| work_keys_str_mv | AT miudovika diacereinasthedrugofchoiceinthetherapyofkneeosteoarthritiswithsecondaryrecurrentsynovitis |